Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study

Affiliations

• ¹ Singapore General Hospital, Singapore, Singapore.
• ² Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA.
• ³ University Medical Center Groningen, Groningen, The Netherlands.
• ⁴ National Heart Center Singapore and SingHealth Duke-NUS, Singapore, Singapore.
• ⁵ The George Institute for Global Health, Sydney, New South Wales, Australia.
• ⁶ University of North Carolina, Chapel Hill, North Carolina, USA.
• ⁷ Keio University School of Medicine, Tokyo, Japan.
• ⁸ Karolinska Institutet, Stockholm, Sweden.
• ⁹ University of Oslo and Oslo University Hospital, Oslo, Norway.
• ¹⁰ University of Ulm, Ulm, Germany.
• ¹¹ Hospital de la Santa Creu i Sant Pau, CIBERDEM, IIB Sant Pau, Barcelona, Spain.
• ¹² University of Manitoba, Winnipeg, Manitoba, Canada.
• ¹³ Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
• ¹⁴ Statisticon AB, Uppsala, Sweden.
• ¹⁵ Catholic University of the Sacred Heart, School of Medicine and Surgery, Rome, Italy.
• ¹⁶ Biomagnetism and Clinical Physiology International Center (BACPIC), Rome, Italy.
• ¹⁷ AstraZeneca SpA, Milan, Italy.
• ¹⁸ Ajou University School of Medicine, Suwon, Republic of Korea.